11 completed, 5 recruiting, 5 unknown, 2 active not recruiting. 15 Phase 2, 12 Phase 3, 3 Phase 1.
Follow Chemotherapy-Induced Thrombocytopenia: new trials by email Literature Review of Chemotherapy-Induced Thrombocytopenia trials Research Report on Chemotherapy-Induced Thrombocytopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Romiplostim N01 for Chemotherapy-induced Thrombocytopenia Romiplostim N01 - Chemotherapy-induced Thrombocytopenia, Romiplostim N01 | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2025-08-01 | 2025-07-14 |
| Romiplostim in Chemotherapy-Induced Thrombocytopenia Romiplostim - Chemotherapy-induced Thrombocytopenia, Solid Malignancy | Phase 3 | Unknown | Ain Shams University | 30 | 2023-12-17 | 2024-01-11 |
| Avatrombopag vs. Placebo for CIT in GI Malignancies Avatrombopag, Matching Placebo - Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 2 | Completed | Hanny Al-Samkari, MD | 49 | 2023-11-01 | 2026-08-31 |
| The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies Hetrombopag - Chemotherapy-induced Thrombocytopenia | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 48 | 2023-10-16 | 2023-10-25 |
| Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma Hetrombopag - Chemotherapy-Induced Thrombocytopenia | Phase 2 | Unknown | Sun Yat-sen University | 90 | 2023-09-04 | 2023-09-06 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia Hetrombopag Olamine - Chemotherapy-Induced Thrombocytopenia | Phase 2 | Not yet recruiting | RenJi Hospital | 72 | 2023-07-01 | 2023-07-13 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. Hetrombopag, Hetrombopag plus Placebo, Placebo - Chemotherapy-Induced Thrombocytopenia | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 213 | 2023-04-25 | 2025-04-16 |
| Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia QL0911, Placebo - Chemotherapy-induced Thrombocytopenia | Phase 2 / Phase 3 | Completed | Qilu Pharmaceutical Co., Ltd. | 63 | 2022-11-08 | 2024-10-18 |
| A Study of PN20 in Healthy Adult Volunteers PN20, Placebo - Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 27 | 2022-06-16 | 2025-03-13 |
| A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia Hetrombopag, Matching placebo - Chemotherapy-Induced Thrombocytopenia | Phase 3 | Withdrawn | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-15 | 2023-09-28 | |
| Herombopag for Chemotherapy-induced Thrombocytopenia Herombopag - Chemotherapy-induced Thrombocytopenia, Herombopag | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2022-03-14 | 2025-02-24 |
| Avatrombopag for Chemotherapy-induced Thrombocytopenia Avatrombopag - Chemotherapy-induced Thrombocytopenia, Avatrombopag | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2022-02-10 | 2025-02-24 |
| Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia QL0911 - Chemotherapy-induced Thrombocytopenia | Phase 2 / Phase 3 | Completed | Qilu Pharmaceutical Co., Ltd. | 50 | 2021-01-15 | 2023-05-09 |
| Eltrombopag for Chemotherapy-induced Thrombocytopenia Eltrombopag - Chemotherapy-induced Thrombocytopenia, Eltrombopag | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2020-12-31 | 2025-02-24 |
| To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment Recombinant Human Interleukin-11 for Injection - Chemotherapy-induced Thrombocytopenia | Completed | Liaoning Cancer Hospital & Institute | 3494 | 2020-09-02 | 2023-01-18 | |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Romiplostim, Placebo - Chemotherapy-induced Thrombocytopenia | Phase 3 | Active not recruiting | Amgen | 145 | 2020-02-26 | 2026-10-19 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. Hetrombopag, Placebo - Chemotherapy-Induced Thrombocytopenia | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 129 | 2019-11-06 | 2025-05-16 |
Showing 20 of 28. Sign in to see all of them.
Thrombocytopenia (7) · Carcinoma, Non-Small-Cell Lung (3) · Gastrointestinal Neoplasms (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Pathologic Complete Response (2) · Digestive System Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hodgkin Disease (1) · Jacobs syndrome (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Blood Platelet Disorders (8) · Cytopenia (8) · Neoplasms (7) · Neoplasms by Site (6) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Digestive System Diseases (3) · Gastrointestinal Diseases (3) · Immune System Diseases (3) · Lung Diseases (3) · Neoplasms by Histologic Type (3)
romiplostim (6) · hetrombopag (5) · avatrombopag (3) · Injections (2) · Interleukin-11 (2) · Tretinoin (2) · oprelvekin (2) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · eltrombopag (1)
Amgen (5) · Institute of Hematology & Blood Diseases Hospital, China (4) · Jiangsu HengRui Medicine Co., Ltd. (3) · Peking University People's Hospital (2) · Qilu Pharmaceutical Co., Ltd. (2) · Ain Shams University (1) · Angde Biotech Pharmaceutical Co., Ltd. (1) · Beijing Northland Biotech. Co., Ltd. (1) · Chongqing Peg-Bio Biopharm Co., Ltd. (1) · Hanny Al-Samkari, MD (1) · Liaoning Cancer Hospital & Institute (1) · Ono Pharma USA Inc (1) · RenJi Hospital (1) · Sobi, Inc. (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
China (15) · United States (6) · Hungary (3) · Poland (3) · Russia (3) · Argentina (2) · Austria (2) · Brazil (2) · Canada (2) · Greece (2) · Italy (2) · Mexico (2) · Peru (2) · Portugal (2) · Romania (2)
Lei Zhang, MD (2) · Xiaohui Zhang, MD (2) · Gerald A Soff, MD (1) · Hanny Al-Samkari, MD (1) · Lei Zhanglei, MD (1) · Liyan Miao (1) · Xiaofeng Han, MD.,Ph.D (1) · Xiaojing Xing (1) · Yi Fang, MD.,Ph.D (1) · Yunfei Chen, MD (1) · Zhiming Li, MD. (1)
2017 (2)